PEAK6
GPCR icon

PEAK6’s Structure Therapeutics GPCR Stock Holding History

PEAK6’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
4,155
-1,900
-31% -$84.1K ﹤0.01% 2243
2026
Q1 		$292K Sell
6,055
-1,900
-24% -$130K ﹤0.01% 2159
2025
Q4 		$553K Sell
7,955
-3,045
-28% -$124K ﹤0.01% 2049
2025
Q3 		$308K Buy
11,000
+1,555
+16% +$31K ﹤0.01% 2325
2025
Q2 		$196K Hold
9,445
– – ﹤0.01% 2458
2025
Q1 		$163K Hold
9,445
– – ﹤0.01% 2495
2024
Q4 		$256K Buy
+9,445
New +$335K ﹤0.01% 2457

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PEAK6's GPCR Position: Q2 2026 in Review

PEAK6 reduced its Structure Therapeutics (GPCR) stake by 31% in Q2 2026, selling an estimated $84.1K and leaving 4,155 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

PEAK6 first reported a position in GPCR in Q4 2024 and has held it in 7 quarters since. The position peaked at $553K in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • PEAK6 held 4,155 shares of Structure Therapeutics worth $223K as of Q2 2026.
  • PEAK6 sold 1,900 Structure Therapeutics shares in Q2 2026, an estimated $84.1K.
  • Structure Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2243 holding.
  • PEAK6 first reported a position in Structure Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • PEAK6's Structure Therapeutics position peaked at $553K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.